Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Decode and Cure primary Focal Segmental Glomerulosclerosis

Project description

Insight into immune causes of kidney disease

Focal segmental glomerulosclerosis (FSGS) is a kidney disease characterised by scarring in the kidney’s filtering units, called glomeruli. This condition can lead to nephrotic syndrome, which involves symptoms such as excess protein in the urine, swelling and low protein levels in the blood. Despite the emphasis on general risk factors like diabetes and hypertension, the specific causes of FSGS remain poorly understood, hindering the development of targeted therapies. The ERC-funded CureFSGS project aims to advance our understanding of immune-mediated causes of FSGS through a molecular classification approach. The research team will decode the immune mediators involved in the disease, aiming to target specific immune cells and injury pathways for enhanced treatment.

Objective

Kidney diseases are a worldwide rising major health problem associated with an excess risk for cardiovascular disease and reduced life expectancy. While general risk factors for kidney diseases such as diabetes and hypertension are being addressed through numerous research efforts, causes of specific glomerular kidney diseases, especially Focal Segmental Glomerulosclerosis (FSGS), remain poorly understood. FSGS is the most common glomerular cause of end stage renal disease characterized by scaring of the glomerular kidney filters and podocytes loss. Until now, the development of specific therapies has been hindered by the poor stratification of FSGS entities and the lack of understanding of immune mediated forms of FSGS. CureFSGS will establish a new strategy to identify key factors in FSGS:
First, CureFSGS will develop a molecular classification of FSGS entities by utilizing a worldwide unique kidney sample repository/ registry combined with a novel analysis pipeline of single cell analytics, multiplex imaging and machine learning-aided image analysis to guide clinical decision making and to provide novel molecular insights.
Second, CureFSGS will precisely decode immune mediators of FSGS and systematically map the podocyte response towards immune actions by devising a novel complementary platform of immune cell analytics and podocyte in vitro, ex vivo perfused kidney, in vivo as well as human organoid systems.
Third, CureFSGS will ultimately precision target the identified immune cells, soluble immune factors or podocyte injury pathways by newly developed cell-specific AAV- and nanobody strategies. Together, CureFSGS will set the stage to finally understand and treat FSGS effectively.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-ERC - HORIZON ERC Grants

See all projects funded under this funding scheme

Call for proposal

(opens in new window) ERC-2023-ADG

See all projects funded under this call

Host institution

UNIVERSITAETSKLINIKUM HAMBURG-EPPENDORF
Net EU contribution
€ 2 500 000,00
Address
Martinistrasse 52
20251 Hamburg
Germany
Region
Hamburg Hamburg Hamburg
Activity type
Higher or Secondary Education Establishments
Links
Total cost
€ 2 500 000,00

Beneficiaries (1)